Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
PZ HTL SA

Resveratrol Shown Effective against Cancer After the Body Converts It

By BiotechDaily International staff writers
Posted on 16 Oct 2013
Study findings show that resveratrol is not rendered ineffective once it is metabolized by the body, contrary to what had been thought earlier.

This is a significant development, since resveratrol is metabolized very rapidly, and it was thought that levels of the extracted chemical drop too quickly to make it usable in clinical trials. The new research revealed that the chemical could still be absorbed into cells after it has been metabolized into resveratrol sulfates. Enzymes within cells are then able to degrade it into resveratrol again, demonstrating that levels of resveratrol in the cells are higher than was previously believed. In fact, the findings appear to show resveratrol may be more effective once it has been generated from resveratrol sulfate than it is if it has never been metabolized because the concentrations achieved are higher.

The investigators led by University of Leicester (UK) translational cancer research specialist Prof. Karen Brown, administered resveratrol sulfate to mice lab models. They were then able to detect free resveratrol in plasma and a range of tissues in the mice.

This is the first direct evidence that resveratrol can be formed from resveratrol sulfate in living animals, and the researchers think it may help to show how resveratrol is able to have beneficial effects in animals. The study also revealed that resveratrol generated from resveratrol sulfate is able to slow the growth of cancer cells by causing them to eat their own internal constituents and blocking them from dividing.

Prof. Karen Brown said, “There is a lot of strong evidence from laboratory models that resveratrol can do a whole host of beneficial things—from protecting against a variety of cancers and heart disease to extending lifespan. It has been known for many years that resveratrol is rapidly converted to sulfate and glucuronide metabolites in humans and animals—meaning the plasma concentrations of resveratrol itself quickly become very low after administration. It has always been difficult to understand how resveratrol is able to have activity in animal models when the concentrations present are so low, and it has made some people skeptical about whether it might have any effects in humans.”

The study’s findings were published October 2, 2013, in the journal Science Translational Medicine. Prof. Brown concluded, “Researchers have hypothesized for a long time that resveratrol might be regenerated from its major metabolites in whole animals but it has never been proven. Our study was the first to show that resveratrol can be regenerated from sulfate metabolites in cells and that this resveratrol can then have biological activity that could be useful in a wide variety of diseases in humans. Importantly, we did all our work with clinically achievable concentrations so we are hopeful that our findings will translate to humans. Overall, I think our findings are very encouraging for all types of medical research on resveratrol. They help to justify future clinical trials where, previously, it may have been difficult to argue that resveratrol can be useful in humans because of the low detectable concentrations. There is considerable commercial interest in developing new forms of resveratrol that can resist or overcome the issue of rapid metabolism. Our results suggest such products may not actually be necessary to deliver biologically active doses of resveratrol to people.”

Dr. Sarah Williams, Cancer Research UK (London) health information officer, said, “This interesting study supports continued research into resveratrol as a therapeutic molecule, but it’s important to note that any benefits from the molecule don’t come from drinking red wine. It’s well established that drinking any type of alcohol, including red wine, increases the risk of developing cancer.”

Related Links:

University of Leicester



Channels

Genomics/Proteomics

view channel
Image: Biopsy of small bowel showing celiac disease manifested by blunting of villi, crypt hyperplasia, and lymphocyte infiltration of crypts (Photo courtesy of Wikimedia Commons).

Reduced Elafin Levels Associated with Celiac Disease Bowel Inflammation

Levels of the enzyme elafin, an endogenous serine protease inhibitor, were lower in the small intestinal epithelium of patients with active celiac disease (CD) as compared to similar tissue from control patients.... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more

Business

view channel

Analytical Sciences Trade Fair Declared a Rousing Success

Organizers of this year's 24th "analytica" biosciences trade fair have reported significant increases in both the number of visitors and exhibitors compared to the 2012 event. The analytica trade fair for laboratory technology, analysis, and biotechnology has been held at the Munich (Germany) Trade Fair Center every... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.